Addition of Selinexor to Bortezomib, Dexamethasone Improves Responses in Myeloma
May 29th 2020The addition of selinexor, a selective inhibitor of nuclear export, to bortezomib and dexamethasone improved progression-free survival across all subgroups in a study of pretreated patients with multiple myeloma.